Experienced in Chronic T-Cell Leukemia (CTCL)

Dr. Leslie L. Popplewell

Hematology | Hematology Oncology
Patient First Inc
2520 Elisha Ave, 
Zion, IL 
Clinical Trials:Currently Recruiting for 2 Trials
Accepting New Patients
Offers Telehealth
29 Years of Experience
Experienced in Chronic T-Cell Leukemia (CTCL)
Patient First Inc
2520 Elisha Ave, 
Zion, IL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Leslie Popplewell is a Hematologist and a Hematologist Oncology provider in Zion, Illinois. Dr. Popplewell has been practicing medicine for over 29 years and is rated as an Experienced provider by MediFind in the treatment of Chronic T-Cell Leukemia (CTCL). Their top areas of expertise are Non-Hodgkin Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma (MCL), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Popplewell is currently accepting new patients.

Their clinical research consists of co-authoring 85 peer reviewed articles and participating in 14 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Hematology Oncology
Licenses
Internal Medicine in AZ
Hospital Affiliations
Midwestern Region Med Center, Inc
Southeastern Regional Medical Center, Inc
Languages Spoken
English

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Network Health
  • HMO

Locations

PATIENT FIRST INC
2520 Elisha Ave, Zion, IL 60099
Other Locations
CITY OF HOPE MEDICAL GROUP OF GEORGIA LLC
600 Celebrate Life Pkwy, Newnan, GA 30265

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

Phase I/II Multi-site Study Evaluating the MTD, Safety and Efficacy of the Combination Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
Phase I/II Multi-site Study Evaluating the MTD, Safety and Efficacy of the Combination Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
Enrollment Status: Recruiting
Publish Date: March 06, 2025
Intervention Type: Drug
Study Drugs: Venetoclax, Lenalidomide, Rituximab
Study Phase: Phase 1/Phase 2
Pilot/Feasibility Study of CMV-Specific CD19-CAR T Cells Plus CMV-MVA Triplex Following Autologous Hematopoietic Stem Cell Transplantation for Patients With Intermediate or High Grade B-Lineage Non-Hodgkin Lymphoma (B-NHL)
Pilot/Feasibility Study of CMV-Specific CD19-CAR T Cells Plus CMV-MVA Triplex Following Autologous Hematopoietic Stem Cell Transplantation for Patients With Intermediate or High Grade B-Lineage Non-Hodgkin Lymphoma (B-NHL)
Enrollment Status: Recruiting
Publish Date: February 18, 2025
Intervention Type: Procedure, Biological
Study Phase: Phase 1
Phase I/II Study of Cellular Immunotherapy Using Central Memory-Enriched CD8+ T Cells Lentivirally Transduced to Express A CD19-Specific Chimeric Immunoreceptor Following Peripheral Blood Stem Cell Transplantation for Patients With High-Risk Intermediate Grade B-Lineage Non-Hodgkin Lymphoma
Phase I/II Study of Cellular Immunotherapy Using Central Memory-Enriched CD8+ T Cells Lentivirally Transduced to Express A CD19-Specific Chimeric Immunoreceptor Following Peripheral Blood Stem Cell Transplantation for Patients With High-Risk Intermediate Grade B-Lineage Non-Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: February 19, 2025
Intervention Type: Biological, Procedure, Other, Drug
Study Drugs: filgrastim, rituximab, genetically engineered lymphocyte therapy, plerixafor
Study Phase: Phase 1/Phase 2
Phase I Study of Cellular Immunotherapy Using Memory-Enriched T Cells Lentivirally Transduced to Express a CD19-Specific, Hinge-Optimized, CD28-Costimulatory Chimeric Receptor and a Truncated EGFR Following Peripheral Blood Stem Cell Transplantation for Patients With High-Risk Intermediate or High Grade B-Lineage Non-Hodgkin Lymphoma
Phase I Study of Cellular Immunotherapy Using Memory-Enriched T Cells Lentivirally Transduced to Express a CD19-Specific, Hinge-Optimized, CD28-Costimulatory Chimeric Receptor and a Truncated EGFR Following Peripheral Blood Stem Cell Transplantation for Patients With High-Risk Intermediate or High Grade B-Lineage Non-Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: February 06, 2025
Intervention Type: Biological, Other
Study Drugs: Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells, Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes
Study Phase: Phase 1
A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
Enrollment Status: Active_not_recruiting
Publish Date: January 23, 2025
Intervention Type: Drug, Other, Procedure
Study Drugs: Carmustine, Cyclophosphamide, Cytarabine, Etoposide, Ibrutinib, Melphalan
Study Phase: Phase 3
A Phase II, Single Arm, Multicenter Open Label Trial to Determine the Efficacy and Safety of Tisagenlecleucel (CTL019) in Adult Patients With Refractory or Relapsed Follicular Lymphoma
A Phase II, Single Arm, Multicenter Open Label Trial to Determine the Efficacy and Safety of Tisagenlecleucel (CTL019) in Adult Patients With Refractory or Relapsed Follicular Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: January 16, 2025
Intervention Type: Biological
Study Drug: Tisagenlecleucel
Study Phase: Phase 2
Phase I Study of Cellular Immunotherapy Using Central Memory-Enriched T Cells Lentivirally Transduced to Express a CD19-Specific, CD28-Costimulatory Chimeric Receptor and a Truncated EGFR Following Peripheral Blood Stem Cell Transplantation for Patients With High-Risk Intermediate Grade B-Lineage Non-Hodgkin Lymphoma
Phase I Study of Cellular Immunotherapy Using Central Memory-Enriched T Cells Lentivirally Transduced to Express a CD19-Specific, CD28-Costimulatory Chimeric Receptor and a Truncated EGFR Following Peripheral Blood Stem Cell Transplantation for Patients With High-Risk Intermediate Grade B-Lineage Non-Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: December 31, 2024
Intervention Type: Biological, Other, Procedure
Study Drug: Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells
Study Phase: Phase 1
A Randomized Phase III Trial of Consolidation With Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs Maintenance Rituximab Alone for Patients With Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission
A Randomized Phase III Trial of Consolidation With Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs Maintenance Rituximab Alone for Patients With Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission
Enrollment Status: Active_not_recruiting
Publish Date: October 26, 2024
Intervention Type: Biological, Procedure
Study Drug: Rituximab
Study Phase: Phase 3
A Phase II Study of IRD (Ixazomib, Lenalidomide, & Dexamethasone) for Consolidation Therapy Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma
A Phase II Study of IRD (Ixazomib, Lenalidomide, & Dexamethasone) for Consolidation Therapy Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: October 01, 2024
Intervention Type: Drug, Biological
Study Drugs: Ixazomib, Lenalidomide, Dexamethasone
Study Phase: Phase 2
A Phase 1b/2 Trial of Hu5F9-G4 in Combination With Rituximab or Rituximab + Chemotherapy in Patients With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
A Phase 1b/2 Trial of Hu5F9-G4 in Combination With Rituximab or Rituximab + Chemotherapy in Patients With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
Enrollment Status: Terminated
Publish Date: May 23, 2024
Intervention Type: Drug
Study Drugs: Magrolimab, Rituximab, Gemcitabine, Oxaliplatin
Study Phase: Phase 1/Phase 2
A Phase II Study of Palbociclib (PD-0332991) in Combination With Ibrutinib in Patients With Previously Treated Mantle Cell Lymphoma
A Phase II Study of Palbociclib (PD-0332991) in Combination With Ibrutinib in Patients With Previously Treated Mantle Cell Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: May 06, 2024
Intervention Type: Drug
Study Drugs: Palbociclib, Ibrutinib
Study Phase: Phase 2
View 9 Less Clinical Trials

85 Total Publications

Real-world outcomes with tisagenlecleucel in aggressive B-cell lymphoma: subgroup analyses from the CIBMTR registry.
Real-world outcomes with tisagenlecleucel in aggressive B-cell lymphoma: subgroup analyses from the CIBMTR registry.
Journal: Journal for immunotherapy of cancer
Published: January 11, 2025
Similar Doctors
Distinguished in Chronic T-Cell Leukemia (CTCL)
Dr. Adam P. Siegel
Hematology Oncology | Hematology | Oncology
Distinguished in Chronic T-Cell Leukemia (CTCL)
Dr. Adam P. Siegel
Hematology Oncology | Hematology | Oncology

Aurora Health Care Metro Inc

36500 Aurora Dr, 
Summit, WI 
 (53.6 mi)
262-434-5000
Experience:
16+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Adam Siegel is a Hematologist Oncology specialist and a Hematologist in Summit, Wisconsin. Dr. Siegel has been practicing medicine for over 16 years and is rated as a Distinguished provider by MediFind in the treatment of Chronic T-Cell Leukemia (CTCL). His top areas of expertise are Chronic T-Cell Leukemia (CTCL), Adult T-Cell Leukemia, Angiosarcoma, and Familial Prostate Cancer. Dr. Siegel is currently accepting new patients.

Advanced in Chronic T-Cell Leukemia (CTCL)
Dr. Mete Korkmaz
Oncology | Hematology | Hematology Oncology
Advanced in Chronic T-Cell Leukemia (CTCL)
Dr. Mete Korkmaz
Oncology | Hematology | Hematology Oncology

Osf Multi-Specialty Group

5666 E State St, 
Rockford, IL 
 (61.5 mi)
815-921-8929
Languages Spoken:
English
See accepted insurances

Mete Korkmaz is an Oncologist and a Hematologist in Rockford, Illinois. Dr. Korkmaz and is rated as a Distinguished provider by MediFind in the treatment of Chronic T-Cell Leukemia (CTCL). His top areas of expertise are Iron Deficiency Anemia, Paget Disease of the Breast, Childhood Iron Deficiency Anemia, Small Cell Lung Cancer (SCLC), and Bone Marrow Aspiration.

Experienced in Chronic T-Cell Leukemia (CTCL)
Dr. Michael E. Keefe
Hematology Oncology | Hematology | Oncology
Experienced in Chronic T-Cell Leukemia (CTCL)
Dr. Michael E. Keefe
Hematology Oncology | Hematology | Oncology

Columbia St Marys Hospital Milwaukee Inc

2301 N Lake Dr, 
Milwaukee, WI 
 (42.4 mi)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Michael Keefe is a Hematologist Oncology specialist and a Hematologist in Milwaukee, Wisconsin. Dr. Keefe and is rated as a Distinguished provider by MediFind in the treatment of Chronic T-Cell Leukemia (CTCL). His top areas of expertise are Thrombocytopenia, Castleman Disease, Multicentric Castleman Disease (MCD), and Unicentric Castleman Disease (UCD). Dr. Keefe is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Popplewell's expertise for a condition
ConditionClose
View All 9 Distinguished Conditions
View All 17 Advanced Conditions
View All 29 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile